Matinas BioPharma Holdings, Inc. (MTNB)
NYSEAMERICAN: MTNB · Real-Time Price · USD
0.1651
+0.0051 (3.19%)
At close: Sep 16, 2026, 4:00 PM EDT
0.1594
-0.0057 (-3.45%)
Pre-market: Sep 17, 2026, 8:50 AM EDT
MTNB Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
2
Market Cap
2.43M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 1.10M | -2.09M | -65.62% |
| Dec 31, 2022 | 3.19M | 3.16M | 9,560.61% |
| Dec 31, 2021 | 33.00K | -125.33K | -79.16% |
| Dec 31, 2020 | 158.33K | 68.52K | 76.29% |
| Dec 31, 2019 | 89.81K | -29.94K | -25.00% |
| Dec 31, 2018 | 119.75K | -29.94K | -20.00% |
| Dec 31, 2017 | 149.69K | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | 194.49K | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| 60 Degrees Pharmaceuticals | 1.21M |
| SciSparc | 856.00K |
| GeoVax Labs | 852.28K |
| Onconetix | 645.82K |
| Silo Pharma | 54.08K |
MTNB News
- 3 days ago - GH Power Signs Multi-Year Hydrogen Offtake Agreement with Change Energy for Hamilton Facility Output - GlobeNewsWire
- 12 days ago - Matinas BioPharma receives noncompliance notifcation from NYSE - TheFly
- 12 days ago - Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards - GlobeNewsWire
- 5 weeks ago - Matinas BioPharma Holdings Quarterly report: Q2 2026 - Filings
- 2 months ago - Matinas BioPharma teams with GH Power to create publicly-traded company - TheFly
- 2 months ago - Matinas BioPharma Announces Strategic Business Combination with GH Power to Create Publicly Traded, Advanced Clean Energy and Green Hydrogen Company; Signs Definitive Agreement to Sell LNC Platform Technology and Lead Product Candidate MAT2203 to Azurity Pharmaceuticals - GlobeNewsWire
- 2 months ago - Matinas BioPharma receives noncompliance notification from NYSE - TheFly
- 2 months ago - Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain Compliance - GlobeNewsWire